• Silo Pharma engaged Resyca to run a drug-device robustness study for SPC-15, its intranasal PTSD candidate using a microchip-based nasal spray system.
• No results have been presented; the study is expected to generate data for a planned FDA Type C meeting request.
• Work aims to confirm consistent device performance and formulation stability to support a first-in-human clinical program.
• Regulatory strategy remains a 505(b)(2) pathway, following alignment reached in a prior pre-IND interaction with the FDA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief on June 29, 2026, and is solely responsible for the information contained therein.